bluuebunny/crossref_metadata_2025_split huggingface dataset:
Chitosan microgels obtained by on-chip crosslinking reaction employing a microfluidic device
Authors: Zamora-Mora Vanessa , Velasco Diego , Hernández Rebeca , Mijangos Carmen 
Published: December 2014

AbstractIn the present work, we report on the preparation of microgels of chitosan crosslinked with sodium tripolyphosphate (TPP) employing the microfluidics technique (MF). To achieve this, several flow focusing geometries were designed and tested. As a first step, a two-inlet flow focusing geometry was employed to emulsify chitosan and the crosslinking reaction was carried out offchip. This procedure did not allow separating the resulting chitosan microgels due to an incomplete crosslinking reaction. A crosslinking reaction on-chip was studied as an alternative. A four-inlet flow focusing geometrywas designed in which three dispersed phases, chitosan 0.25% (w/v), TPP 0.05% (w/v) and acetic acid 1% (v/v) and an continuous phase mineral oil + Span 80 (3% w/v) were employed. The flow rates for the continuous phase were varied from 6.7 to 11.7 μL/min and chitosan microgels were successfully obtained with average diameters from 68 to 42 μm. The average size of the microgels outside the MF device decreased up to ~21% with respect to their size inside the MF device due to partial expulsion of water from the microgels when complete gelation occurred.
On some nonlinear fractional PDEs in physics
Authors: Ahmad Jamshad , Mohyud-Din Syed Tauseef 
Published: December 2014

In this paper, we applied relatively new fractional complex transform (FCT) to convert the given fractional partial differential equations (FPDEs) into corresponding partial differential equations (PDEs) and Variational Iteration Method (VIM) is to find approximate solution of time- fractional Fornberg-Whitham and time-fractional Wu-Zhang equations. The results so obtained are re-stated by making use of inverse transformation which yields it in terms of original variables. It is observed that the proposed algorithm is highly efficient and appropriate for fractional PDEs arising in mathematical physics and hence can be extended to other problems of diversified nonlinear nature. Numerical results coupled with graphical representations explicitly reveal the complete reliability and efficiency of the proposed algorithm. DOI: http://dx.doi.org/10.3126/bibechana.v12i0.11687BIBECHANA 12 (2015) 59-69
Significance of neutrino-neutrino interaction in neutrino oscillation in core-collapse supernova
Authors: Nakarmi Prabandha , Nakarmi Jeevan Jyoti 
Published: December 2014

We study the possibility of neutrino-neutrino interaction inside the neutrino core of supernova (ρ ≥ 1010 g/cc) and outside the neutrinosphere. The angular dependence of the neutrino-neutrino interaction Hamiltonian causes multi-angle effects that can lead either to oscillation or free streaming of neutrinos. If the angle between interactions is π/2, the neutrinos are trapped inside neutrino core and chances of oscillation increases due to interaction. As the angle gradually changes, the chance of oscillation decreases and free streaming of neutrino can be observed out of core of supernova as shock waves.DOI: http://dx.doi.org/10.3126/bibechana.v12i0.11780 BIBECHANA 12 (2015) 89-95
On contact conformal curvature tensor in trans-Sasakian manifolds
Authors: Shah Riddhi Jung 
Published: December 2014

The purpose of this paper is to study some results on contact conformal curvature tensor in trans-Sasakian manifolds. Contact conformally flat trans-Sasakian manifold, ζ-contact conformally flat trans-Sasakian manifold and curvature conditions C0(ζ.X).S = 0 and C0(ζ.X).C0 = 0 are studied with some interesting results. Finally, we study an example of 3-dimensional trans-Sasakian manifold. DOI: http://dx.doi.org/10.3126/bibechana.v12i0.11783 BIBECHANA 12 (2015) 80-88
De la loi 2002-2 aux États généraux du travail social ( egts ) : deux voies pour la (re)construction d'une légitimité
Authors: Jaeger Marcel 
Published: December 2014

Les travailleurs sociaux sont de plus en plus souvent en difficulté dans leur relation au mandat qui leur est confié sans que celui-ci soit toujours très clair ou sans que les conditions soient réunies pour qu’ils le remplissent. Ils sont ainsi confrontés à une crise de légitimité pour laquelle deux voies de sortie sont envisagées : une redéfinition de leur cadre d’action par la loi et une formule en cours d’expérimentation, les États généraux du travail social, comme étape d’un processus de refondation.
L'accompagnement à la professionnalisation des bénévoles : pour quelle(s) légitimité(s) ?
Authors: Tardif Bourgoin Florence 
Published: December 2014

Dans un contexte de professionnalisation associative (centres sociaux), le développement de la qualité et de l’évaluation vient renforcer une logique de compétences attendues du côté des bénévoles alors même que la dimension « formative » de leur engagement est inscrite historiquement dans un projet d’éducation populaire (au service d’une mutualisation des savoirs). L’organisation du rôle des bénévoles repose alors sur l’importation de méthodes « professionnelles » permettant de garantir le respect des règles de l’intervention sociale. Cela passe par des recrutements formalisés (compétences) et des temps de formation qui présentent des analogies avec les dispositifs classiques. Si la légitimité professionnelle repose sur la reconnaissance des activités de travail (formation et diplôme), sur quelle légitimité repose la formation des bénévoles ? Quelle place occupe-t-elle dans les logiques d’organisation, dans le déploiement des activités, dans les perspectives individuelles d’engagement ?
Problème de légitimité et reconnaissance : la plainte des assistants de service social à l'hôpital psychiatrique aujourd'hui
Authors: Leshaf Nacer 
Published: December 2014

Les réformes que connaît l’institution hospitalière depuis ces vingt dernières années ont provoqué des modifications dans les organisations du travail et bousculé la pratique des professionnels. À l’hôpital psychiatrique, les assistants sociaux vivent mal ces bouleversements. Leurs plaintes répétées font irruption à tout moment, aussi bien dans des espaces formels qu’informels. Ils expriment un sentiment d’impuissance à apporter des solutions adaptées aux patients et à satisfaire l’attente d’un corps médical également sous pression. Ce travail de recherche en deis s’est intéressé au sens « explicite et caché » de ces discours dans les organisations. Ils traduiraient à la fois un sentiment de disqualification, de déclassement, et s’inscriraient dans une stratégie de ces acteurs afin de préserver leur position dans l’organisation et sauvegarder la pratique de leur métier. Tout cela dans un contexte de changement organisationnel important.
Burgemeester en mediation
Authors: Kil Ad , de Jonge Tanja 
Published: December 2014

Mayor and Mediation – Views on the Future of Mediation as a Tool in Local Public Administration
In recent years in The Netherlands around 120 mayors were trained as mediator. Focus of this multi method research was to collect the view of those mayors on – the future of - mediation as a tool in local public administration. More specific in conflicts with citizens, industry and other shareholders. Response rates on online survey was below standards but yield some descriptive aspects of this mayor group. Focus groups were informative. Mediation in local public administration is an accepted and successful phenomenon fact and will be further incorporated. Those mayors were pioneers and innovators but want to pass this method to organizational levels. One plead for incorporating principles and practice of mediation in all administrative processes and protocols.
Bemiddeling in de rechtbank van koophandel Gent
Authors: Bruggeman Maria 
Published: December 2014

Mediation in the Commercial Court of Ghent
In the Commercial Court of Ghent a 5th chamber has been created in each division, with the view to proposing an alternative dispute resolution method, such as a conciliation in front of and with the assistance of the judge or a referral to an external meditation.The author points out that files can be directed to this chamber not only at the time of introduction of the court case but also at the time the procedural calendar is set after the respondent has filed the first written submission. Even after the pleadings and after an interlocutory judgment has been rendered, the 5th chamber of the Commercial Court can still refer the matter to an external mediation.All cases in the field of construction, internal companies disputes and commercial agency can also be automatically referred to this chamber.The author believes that is it not the task of a judge to act as a mediator because judges are trained to decide themselves about disputes and because they do not have enough time for a mediation. However, the creation of the 5th chamber could give a boost to external mediation knowing that 75% of the attempted mediations end successfully with a settlement.
Large pipeline and new safety issues likely to change 1st line recommendations for multiple sclerosis
Authors: Kamm Gayle 
Published: December 2014

ABSTRACT
Multiple Sclerosis (MS) is chronic neurodegenerative disorder which can result in significant morbidity. Currently, there are not evidence-based guidelines for the choice of which first-line agent to start with, when to switch, or what to switch to, when treating MS. This review article discusses recent changes related to the treatment of MS and reviews disease modifying therapies in the pipeline for treatment of relapsing-remitting multiple sclerosis.
Aripiprazole induced hiccups
Authors: Kattura Rania , Shet Prakeh 
Published: December 2014

Hiccups are a product of involuntary, intermittent spasmodic contraction of the diaphragm and inspiratory intercostal muscles that results in sudden inspiration and abrupt closure of the glottis. The exact pathophysiology of hiccups remains unknown. However, certain neurotransmitters, medications, and other factors have been implicated.
We report a case of a 38 year old patient who developed hiccups three days after adding aripiprazole 5 mg once a day to his medication regimen. Medical and environmental causes were ruled out and aripiprazole was discontinued. One day later, the hiccups resolved.
Several case reports have described patients who developed hiccups when treated with aripiprazole and related this to changes in neurotransmitter concentrations. However, due to limited literature, it was difficult to determine rate of occurrence of this adverse event with aripiprazole.
A temporal but not a causal relationship was observed between initiating aripiprazole and development of hiccups in this patient. A causal relationship cannot be established since the patient was not re-challenged with aripiprazole. Nonetheless, clinicians should be cognizant that use of aripiprazole may be associated with hiccups.
Implementation of antipsychotic selection recommendations at a veterans affairs facility
Authors: Clark Jeff , Gold Jeff , Hawk Sherri 
Published: December 2014

Introduction: In 2012, the Veterans Affairs (VA) Pharmacy Benefits Management Services created recommendations for antipsychotic selection in schizophrenia and schizoaffective disorders. The recommendations stated that patients must fail two first line agents (haloperidol, loxapine, quetiapine, risperidone or perphenazine) and clozapine (if appropriate) before being allowed to trial second line agents olanzapine, ziprasidone or aripiprazole. The aim of this project was to determine the amount of cost savings that could have been provided had the above recommendations been implemented last year.
Use of second generation antipsychotics has been associated with weight gain, diabetes, and worsening lipid profiles. The American Diabetes Association (ADA) has created guidelines regarding cardiometabolic monitoring of second generation antipsychotic agents. A secondary aim of this project was to determine the rate of provider adherence to the ADA recommendations.

Methods: A retrospective chart review was performed for patients >18 years of age who were initiated on aripiprazole, ziprasidone, or olanzapine for all indications between July 1, 2011 and July 1, 2012. The costs of the mean doses of these agents were compared to an equivalent mean dose of the first line agent risperidone (4mg) using VA drug acquisition costs.
Cardiometabolic monitoring data were collected to include weight, blood pressure, fasting glucose and fasting lipid profiles at baseline and at 12 weeks.

Results: Of the 542 patients started on second line agents, only 68 met criteria for their use. A potential cost savings of over $850,000 may have been realized had these criteria been enacted within the one year time period studied.
None of the 542 patients had both baseline and follow-up values for weight, blood pressure, fasting glucose and fasting lipid profiles. While roughly 60% of patients had blood pressure and weight values at baseline and 27% had glucose and cholesterol values, less than 14% received follow-up testing with approximately 2% receiving neither baseline nor follow-up testing.

Discussion: Significant cost savings can be realized via the use of selection criteria without sacrificing efficacy as most studies do not demonstrate the superiority of one agent and the rates of adverse events between first and second generation agents are more similar than previously thought. This study also highlighted the lack of adequate cardiometabolic monitoring which could lead to cardiovascular disease.
Utilization of a psychiatric clinical pharmacist in an integrated behavioral health program of a community health center
Authors: Silvia Richard J. 
Published: December 2014

Treatment of mental illnesses has slowly shifted to primary care settings over the past decade. As more patients are identified as needing treatment for a mental illness, the availability of behavioral health (BH) practitioners has become more strained, leading to this shift towards primary care treatment. With more patients receiving psychiatric health care from their primary care providers (PCP), a need for dedicated BH practitioners within the primary care setting was developed.
This article describes a novel program where a clinical psychiatric pharmacist is utilized as the primary psychiatric provider within an integrated BH program of a busy primary care clinic in a major metropolitan area. Working under a collaborative practice agreement to prescribe, the pharmacist acts as the initial BH contact for the clinic, as well as a liaison between primary care and BH. Patients referred to the pharmacist from primary care are then evaluated and appropriate medication prescribed for their illness. Most patients are followed prospectively by the pharmacist, with more complex patients (i.e., those not appropriate for primary care-based BH treatment) referred to the BH clinic for follow-up care. The pharmacist serves on the intake committee for the BH clinic, and facilitates patient referrals to their clinicians.
Preliminary analysis of the program's effectiveness shows positive results. Within the first two months of the program, 28 patients were referred to the pharmacist (including five referred by BH clinic therapists through primary care). Most patients were referred for depression or anxiety, with attention deficit hyperactivity disorder, substance abuse, bipolar disorder, and psychosis also being treated. As such, antidepressants and anxiolytics were the most common agents prescribed, but most every class of psychotherapeutic agents was utilized. Patient wait times to meet with the pharmacist were generally less than a week, with exceptions being found for patients already being prescribed a psychotherapeutic agent by their PCP and being referred to the pharmacist for follow-up care, or for patients being referred by their existing therapist. Initial reviews of the program by patients, primary care staff, and BH staff have been positive, especially in regards to patient access to specialized BH services.
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Authors: King Brett , Ko Justin , Kwon Ohsang , Vañó-Galván Sergio , Piraccini Bianca Maria , Dutronc Yves , Yu Guanglei , Liu Chunyuan , Somani Najwa , Ball Susan , Mesinkovska Natasha A. 
Published: August 2024

ImportanceBaricitinib has demonstrated efficacy for treating severe alopecia areata in adults. There is currently limited information about the need for continuous therapy after achieving scalp hair regrowth.ObjectiveTo report results from the randomized withdrawal period of the BRAVE-AA1 trial.Design, Setting, and ParticipantsBRAVE-AA1 was a randomized, placebo-controlled, phase 3 randomized clinical trial with a treatment withdrawal substudy that was conducted at 70 centers in 3 countries beginning in March 2019. It included 654 adults with severe alopecia areata (AA) (Severity of Alopecia Tool [SALT] score ≥50) who were randomized 3:2:2 to receive treatment with baricitinib, 4 mg; baricitinib, 2 mg; or placebo. Data were analyzed in August 2023.InterventionAt week 52, 154 patients who were responders (SALT score ≤20) were rerandomized 3:1 to continue to take their current dose of baricitinib or transition to placebo (randomized withdrawal). Responders randomized to placebo who experienced a loss of treatment benefit (&amp;gt;20-point worsening in SALT score) at any time after week 52 were retreated with their original baricitinib dose.Main Outcome and MeasuresThe proportion of patients who lost treatment benefit through week 152 and the proportion of patients who recaptured response after retreatment. The last observation carried forward was used to impute missing or censored data.ResultsOf 654 patients who received treatment, the mean (SD) age was 37.1 (13.0) years, and there were 383 women (58.6%). At week 52, 10 of 39 responders taking baricitinib, 2 mg, and 30 of 115 responders taking baricitinib, 4 mg, were rerandomized to placebo. At 4 and 8 weeks of treatment withdrawal, 0% and 10% to 11% of patients, respectively, lost treatment benefit regardless of dose. At week 152, 80% of patients had lost benefit compared with 7% for those who continued baricitinib therapy for both dose groups. Within the follow-up observation periods, 5 of 8 patients taking 2 mg (63%) and 21 of 24 patients taking 4 mg (87.5%) recaptured a SALT score of 20 or less response after retreatment.Conclusions and RelevanceSevere AA is a chronic, relapsing condition, and this randomized clinical trial found that withdrawal of therapy for a patient population with severe AA who had achieved meaningful hair regrowth after 1 year of treatment with baricitinib resulted in loss of benefit for almost all patients, indicating that continued therapy is required to maintain hair regrowth.Trial RegistrationClinicalTrials.gov Identifier: NCT03570749
Long-Term Survival in Patients With Advanced Melanoma
Authors: van Not Olivier J. , van den Eertwegh Alfons J. M. , Jalving Hilde , Bloem Manja , Haanen John B. , van Rijn Rozemarijn S. , Aarts Maureen J. B. , van den Berkmortel Franchette W. P. J. , Blank Christian U. , Boers-Sonderen Marye J. , de Groot J. W. B. Jan Willem , Hospers Geke A. P. , Kapiteijn Ellen , Leeneman Brenda , D. Piersma , Stevense-den Boer Marion , van der Veldt Astrid A. M. , Vreugdenhil G. Gerard , Wouters Michel W. J. M. , Blokx Willeke A. M. , Suijkerbuijk Karijn P. M. 
Published: August 2024

IMPORTANCELong-term survival data from clinical trials show that survival curves of patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting that patients have a chance of achieving long-term survival.OBJECTIVETo investigate long-term survival in patients with advanced melanoma treated with ICIs outside clinical trials.DESIGN, SETTING, AND PARTICIPANTSCohort study using prospectively collected data from the nationwide Dutch Melanoma Treatment Registry, including patients in the Netherlands with advanced melanoma treated with first-line ICIs from 2012 to 2019. Data were analyzed from January to September 2023.EXPOSURESPatients were treated with first-line ipilimumab-nivolumab, antibodies that target programmed cell death (anti–PD-1), or ipilimumab.MAIN OUTCOMES AND MEASURESProgression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox proportional hazards model was used to investigate factors associated with PFS after reaching partial response (PR) or complete response (CR).RESULTSA total of 2490 patients treated with first-line ICIs were included (median [IQR] age, 65.0 [55.3-73.0] years; 1561 male patients [62.7%]). Most patients had an Eastern Cooperative Oncology Group Performance Status of 1 or lower (2202 patients [88.5%]) and normal lactate dehydrogenase levels (1715 patients [68.9%]). PFS for all patients was 23.4% (95% CI, 21.7%-25.2%) after 3 years and 19.7% (95% CI, 18.0%-21.4%) after 5 years. Overall survival for all patients was 44.0% (95% CI, 42.1%-46.1%) after 3 years and 35.9% (95% CI, 33.9%-38.0%) after 5 years. Patients with metastases in 3 or more organ sites had a significantly higher hazard of progression after reaching PR or CR (adjusted hazard ratio, 1.37; 95% CI, 1.11-1.69).CONCLUSIONS AND RELEVANCEThis cohort study of patients with advanced melanoma treated with ICIs in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. These findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.